R. Gasiorowski

发表

Formalising multidisciplinary peer review: developing a haematological malignancy‐specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence‐based clinical practice

J. Fletcher, J. Trotman, J. Estell, 2017, Internal medicine journal.

Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol

A. Schwarer, D. Joshua, S. Avery, 2014, Leukemia & lymphoma.

Examination of CD302 as a potential therapeutic target for acute myeloid leukemia

F. Kupresanin, P. Fromm, P. Silveira, 2019, PloS one.

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.

N. Johnson, A. Santoro, P. Zinzani, 2021, The Lancet. Oncology.

CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation

P. Hogarth, M. Kennerson, F. Kupresanin, 2019, Molecular oncology.

Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma

M. Waltham, L. Kats, S. Opat, 2022, Leukemia.

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

N. Johnson, A. Santoro, P. Zinzani, 2021, Blood advances.

Study protocol for a randomised controlled trial examining the effect of blood and plasma donation on serum perfluoroalkyl and polyfluoroalkyl substance (PFAS) levels in firefighters

M. Forbes, M. Taylor, G. Silver, 2021, BMJ Open.

Effect of Plasma and Blood Donations on Levels of Perfluoroalkyl and Polyfluoroalkyl Substances in Firefighters in Australia

B. Lanphear, M. Forbes, R. Klein, 2022, JAMA network open.

Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia

C. Tam, J. Trotman, E. Verner, 2018, Haematologica.

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

N. Johnson, A. Santoro, P. Zinzani, 2020, Journal of Clinical Oncology.

A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.

R. Greil, G. Salles, A. Zelenetz, 2020, Blood.

CD300 molecule regulation of human dendritic cell functions.

X. Ju, G. Clark, D. Hart, 2013, Immunology letters.

New insights into the phenotype of human dendritic cell populations

James W. Young, R. Cabezón, D. Benítez-Ribas, 2016, Clinical & translational immunology.

A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission

J. Hsu, H. McGuire, B. Kong, 2017, Oncoimmunology.

Antibody therapy for acute myeloid leukaemia

K. Bradstock, G. Clark, D. Hart, 2014, British journal of haematology.

Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia?

P. Silveira, G. Clark, Edward Abadir, 2020, Journal of clinical medicine.

Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B‐cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance

Caitlin E. Coombes, M. Dickinson, D. Talaulikar, 2019, British journal of haematology.

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.

R. Greil, G. Salles, A. Zelenetz, 2021, Blood.

Dasatinib-induced colitis: a case report.

P. Katelaris, R. Gasiorowski, A. Tamilarasan, 2019, Pathology.

Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia.

Ahmed H. Mekkawy, G. Pietersz, P. Silveira, 2020, Blood advances.

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic

S. Mulligan, C. Tam, H. Prince, 2020, Internal medicine journal.

Rapidly fatal post-allogeneic stem cell transplant lymphoproliferative disorder presenting with skin and bone marrow involvement.

J. Trotman, J. Gibson, S. Larsen, 2013, Pathology.

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

T. Phillips, P. Lugtenburg, M. Hutchings, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Favezelimab (anti–LAG-3) plus pembrolizumab in patients with anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.

N. Johnson, J. Kuruvilla, J. Timmerman, 2022, Journal of Clinical Oncology.

CAR-T for follicular lymphoma: are we good to go?

J. Trotman, R. Gasiorowski, 2022, Blood.

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

N. Johnson, J. Kuruvilla, J. Timmerman, 2022, Blood.

P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY

N. Johnson, J. Kuruvilla, J. Timmerman, 2022, HemaSphere.

SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA: LONGER FOLLOW‐UP FROM THE PIVOTAL EPCORE NHL‐1 TRIAL

M. Hutchings, C. Cheah, C. Thieblemont, 2023, Hematological Oncology.

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

T. Phillips, P. Lugtenburg, M. Hutchings, 2022, Blood.

Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.

P. Lugtenburg, M. Hutchings, C. Cheah, 2023, Journal of Clinical Oncology.

Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study

R. Greil, G. Salles, A. Zelenetz, 2018, Blood.

Antibody therapy for acute myeloid leukaemia

K. Bradstock, G. Clark, D. Hart, 2014, British journal of haematology.

Rapidly fatal post-allogeneic stem cell transplant lymphoproliferative disorder presenting with skin and bone marrow involvement.

J. Trotman, J. Gibson, S. Larsen, 2013, Pathology.

PS1028 ALLG APML5: A COMPARATIVE BIOAVAILABILITY STUDY OF ENCAPSULATED ORAL ARSENIC TRIOXIDE AND INTRAVENOUS ARSENIC TRIOXIDE IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA UNDERGOING CONSOLIDATION THERAPY

A. Boddy, P. Marlton, S. Lane, 2019, HemaSphere.